Broadfin Buffs Up on Zogenix, Inc. (ZGNX) and Derma Sciences Inc (DSCI)

Among over 700 hedge funds that we track the largest stake holders in Zogenix, Inc. (NASDAQ:ZGNX) besides Broadfin were Steven Boyd’s Armistice Capital with 9.4 million shares valued at 12.88 million and Julian Baker and Felix Baker’s Baker Bros. Advisors with 2.35 million shares valued at $3.2 million.

Derma Sciences Inc (NASDAQ:DSCI) gained popularity among the hedge funds during the fourth quarter as the number of funds invested in the company swelled to 18 with total investment of $117.26 million versus 16 firms with $95.28 million. Baker Bros. Advisors and Mitchell Blutt’s Consonance Capital Management were significant stakeholders in the company with their respective holdings being 3.53 million shares valued at $32.93 million and 1.63 million shares valued at $15.2 million.

Derma Sciences Inc (NASDAQ:DSCI) is a tissue regeneration company which is focused on three segments of the wound care marketplace: advanced wound care, traditional wound care, and pharmaceutical wound care. The company’s stock price has declined by nearly 32% over the last year. Although net loss per share of $0.37 beat estimates by $0.08, fourth quarter revenues of $22.87 million came in $0.04 million lighter than expected.

Derma Sciences Inc (NASDAQ:DSCI) also hit its new 52 week low just last week and Broadfin’s move to increase its stake in the company comes amid this recent slump. Derma is a company that operates in the advanced medical equipment and technology industry. However, over the last year, unlike  Derma Sciences Inc (NASDAQ:DSCI), the industry has performed exceptionally well, outperforming the S&P 500 by 16 percentage points.

Disclosure: none